Low Fasting Plasma Insulin is Associated Atrial Fibrillation in Men from a Cohort Study--the Malmö Preventive Project

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2014 Aug 25

PMID 25150967

Citations 5

Authors

Linda S B Johnson

Tord Juhlin

Gunnar Engstrom

Peter M Nilsson

Affiliations

Soon will be listed here.

Abstract

Background: Type 2 diabetes has been associated with increased incidence of atrial fibrillation (AF) and cardiovascular disease. Controversy remains regarding the role of insulin in the epidemiology of AF risk. The aim of the present study was to study the association between fasting plasma insulin (FPI) and incidence of AF, as well as any effect modification by fasting blood glucose (FBG) or 2 h post-load blood glucose and body mass index (BMI).

Methods: The study population consisted of 6052 men and 1014 women followed for an average of 26.2 years. There were 983 cases of incident AF. Analysis was performed using Cox regression and competing risks regression approaches. The population was analysed as a whole, and by subgroups according to glucose levels and BMI.

Results: After adjustment for age, height, weight, systolic blood pressure and smoking there was a significant inverse association between FPI and AF (hazard ratio; HR) for 4th vs. 1st quartile: 0.69 (95% confidence interval (CI): 0.57-0.83, p < 0.0001) in the cohort as a whole. Among men the corresponding values were HR 0.64 (95% CI 0.52-0.78, p < 0.001) and among women HR 1.16 (95% CI 0.69-1.93, p = 0.58); p-value for interaction 0.06. The protective effects of insulin tended to be weaker in subjects with elevated fasting glucose, implying that the relation between FPI and incident AF could be dependent on the status of individual's glucose metabolism.

Conclusions: High levels of FPI are associated with lower risk of incident AF in a middle-aged population with a long follow-up.

Citing Articles

Metabolic Inflexibility as a Pathogenic Basis for Atrial Fibrillation.

Qin X, Zhang Y, Zheng Q Int J Mol Sci. 2022; 23(15).

PMID: 35955426 PMC: 9368187. DOI: 10.3390/ijms23158291.

Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies.

Lee T, Lee T, Lin Y, Chen Y, Kao Y, Chen Y Cell Mol Life Sci. 2020; 78(3):923-934.

PMID: 32965513 PMC: 11072414. DOI: 10.1007/s00018-020-03648-y.

The Association Between Diabetes Mellitus and Atrial Fibrillation: Clinical and Mechanistic Insights.

Bohne L, Johnson D, Rose R, Wilton S, Gillis A Front Physiol. 2019; 10:135.

PMID: 30863315 PMC: 6399657. DOI: 10.3389/fphys.2019.00135.

Autoimmune activation as a determinant of atrial fibrillation among Turks: A prospective evaluation.

Simsek B, Altay S, Ozbilgin N, Onat A Medicine (Baltimore). 2018; 97(31):e11779.

PMID: 30075607 PMC: 6081191. DOI: 10.1097/MD.0000000000011779.

A Machine Learning Aided Systematic Review and Meta-Analysis of the Relative Risk of Atrial Fibrillation in Patients With Diabetes Mellitus.

Xiong Z, Liu T, Tse G, Gong M, Gladding P, Smaill B Front Physiol. 2018; 9:835.

PMID: 30018571 PMC: 6037848. DOI: 10.3389/fphys.2018.00835.

References

Waldo A . Inter-relationships between atrial flutter and atrial fibrillation. Pacing Clin Electrophysiol. 2003; 26(7 Pt 2):1583-96. DOI: 10.1046/j.1460-9592.2003.t01-1-00236.x. View

Fontes J, Lyass A, Massaro J, Rienstra M, Dallmeier D, Schnabel R . Insulin resistance and atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2011; 109(1):87-90. PMC: 3242834. DOI: 10.1016/j.amjcard.2011.08.008. View

Tang R, Gao L, Dong J, Liu X, Liu X, Wu J . Metabolic syndrome in patients with atrial fibrillation in the absence of structural heart disease from a tertiary hospital in China. Chin Med J (Engl). 2009; 122(22):2744-7. View

Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden D, Sasaki S . Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation. 2008; 117(10):1255-60. PMC: 2637133. DOI: 10.1161/CIRCULATIONAHA.107.744466. View

Huxley R, Alonso A, Lopez F, Filion K, Agarwal S, Loehr L . Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart. 2011; 98(2):133-8. PMC: 3237721. DOI: 10.1136/heartjnl-2011-300503. View

Vyssoulis G, Karpanou E, Adamopoulos D, Kyvelou S, Tzamou V, Michaelidis A . Metabolic syndrome and atrial fibrillation in patients with essential hypertension. Nutr Metab Cardiovasc Dis. 2011; 23(2):109-14. DOI: 10.1016/j.numecd.2011.03.011. View

Huxley R, Lopez F, Folsom A, Agarwal S, Loehr L, Soliman E . Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123(14):1501-8. PMC: 3181498. DOI: 10.1161/CIRCULATIONAHA.110.009035. View

DeFronzo R, Mehta R, Schnure J . Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract (1995). 2013; 41(2):132-47. DOI: 10.3810/hp.2013.04.1062. View

Smith J, Platonov P, Hedblad B, Engstrom G, Melander O . Atrial fibrillation in the Malmö Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol. 2009; 25(2):95-102. DOI: 10.1007/s10654-009-9404-1. View

10.

Kristenson H, Trell E . Indicators of alcohol consumption: comparisons between a questionnaire (Mm-MAST), interviews and serum gamma-glutamyl transferase (GGT) in a health survey of middle-aged males. Br J Addict. 1982; 77(3):297-304. DOI: 10.1111/j.1360-0443.1982.tb02459.x. View

11.

Heeringa J, Kors J, Hofman A, van Rooij F, Witteman J . Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. Am Heart J. 2008; 156(6):1163-9. DOI: 10.1016/j.ahj.2008.08.003. View

12.

Knuiman M, Briffa T, Divitini M, Chew D, Eikelboom J, McQuillan B . A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. Eur J Epidemiol. 2014; 29(3):181-90. DOI: 10.1007/s10654-013-9875-y. View

13.

Dublin S, Glazer N, Smith N, Psaty B, Lumley T, Wiggins K . Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med. 2010; 25(8):853-8. PMC: 2896589. DOI: 10.1007/s11606-010-1340-y. View

14.

Anderson E, Hoffman R, Balon T, Sinkey C, Mark A . Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991; 87(6):2246-52. PMC: 296986. DOI: 10.1172/JCI115260. View

15.

Larstorp A, Ariansen I, Gjesdal K, Olsen M, Ibsen H, Devereux R . Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension. 2012; 60(2):347-53. DOI: 10.1161/HYPERTENSIONAHA.112.195032. View

16.

Muniyappa R, Sowers J . Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013; 14(1):5-12. PMC: 3594115. DOI: 10.1007/s11154-012-9229-1. View

17.

Berglund G, Nilsson P, Eriksson K, Nilsson J, Hedblad B, Kristenson H . Long-term outcome of the Malmö preventive project: mortality and cardiovascular morbidity. J Intern Med. 2000; 247(1):19-29. DOI: 10.1046/j.1365-2796.2000.00568.x. View

18.

Huxley R, Filion K, Konety S, Alonso A . Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011; 108(1):56-62. PMC: 3181495. DOI: 10.1016/j.amjcard.2011.03.004. View

19.

Baron A, Johnson A, Hardin D . Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension. 1993; 21(2):129-35. DOI: 10.1161/01.hyp.21.2.129. View

20.

Benjamin E, Levy D, Vaziri S, DAgostino R, Belanger A, Wolf P . Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994; 271(11):840-4. View